EUVIMEDEUVIMED entdecken
Crossref

Pharmacokinetics and Metabolism of ARV‐393, a BCL6 PROTAC Degrader, in Dogs by UPLC–MS/MS and UPLC‐Q‐Exactive Orbitrap‐HRMS

Qiuyan Wang, Rui Li, Huiying Zhang iD

Biomedical Chromatography · 2026-07 · 40 (7)

DOI: 10.1002/bmc.70498 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 26.05.2026. Verfasst von Qiuyan Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Xuzhou Central Hospital Affiliated Southeast University, Xuzhou, Jiangsu Province, China. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Liquid Chromatography-Mass Spectrometry. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ARV‐393 is a novel PROTAC designed to degrade B‐cell lymphoma 6. To support its further development, it is necessary to disclose the pharmacokinetic and metabolism profiles. To achieve this goal, in this study, a simple and sensitive UPLC‐MS/MS method was developed for the quantification of ARV‐393 and a UPLC‐Q‐Exactive Orbitrap‐HRMS method was utilized to identify its metabolites in dog plasma. After acetonitrile‐mediated protein precipitation, the sample was separated on a Waters ACQUITY BEH C 18 column (50 mm × 2.1 mm, 1.7 μm). The mobile phase consisted of 2 mM of ammonium acetate and acetonitrile, each containing 0.1% formic acid, delivered at 0.4 mL/min. The analyte and internal standard were quantified using the transitions of m/z 898.2 → 398.2 and m/z 724.4 → 396.2, respectively. The method demonstrated excellent linearity over the concentration range of 1.0–1000 ng/mL ( r > 0.998). The validated method was successfully applied to a pharmacokinetic study of ARV‐393 in dogs. The results indicated that ARV‐393 exhibits low clearance and favorable bioavailability (64.7%). Four metabolites were tentatively identified by accurate mass and fragment ions. The proposed metabolic pathways include hydroxylation and hydrolysis. This work provides an overview of the pharmacokinetic and metabolism of ARV‐393, laying a foundation for further development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tandem Mass SpectrometryLiquid Chromatography-Mass SpectrometryAnimalsDogsReproducibility of ResultsChromatography, High Pressure LiquidProteolysis Targeting ChimeraLinear ModelsMaleLimit of DetectionSensitivity and Specificity

Stichwörter der Autor:innen

ARV‐393BCL6 PROTACmetabolitemethod validationpharmacokinetics

Substanzen

Proteolysis Targeting Chimera

Autor:innen und Institutionen

  • Department of Pharmacy, Xuzhou Central Hospital Affiliated Southeast University, Xuzhou, Jiangsu Province, China.
  • Department of Clinical Pharmacy, Xuzhou Central Hospital Affiliated Southeast University, Xuzhou, Jiangsu Province, China.

ORCID-Profile: Huiying Zhang

Zitieren

APA

Wang, Q., Li, R., & Zhang, H. (2026). Pharmacokinetics and Metabolism of ARV‐393, a BCL6 PROTAC Degrader, in Dogs by UPLC–MS/MS and UPLC‐Q‐Exactive Orbitrap‐HRMS. Biomedical Chromatography, 40(7). https://doi.org/10.1002/bmc.70498

Vancouver

Wang Q, Li R, Zhang H. Pharmacokinetics and Metabolism of ARV‐393, a BCL6 PROTAC Degrader, in Dogs by UPLC–MS/MS and UPLC‐Q‐Exactive Orbitrap‐HRMS. Biomedical Chromatography. 2026;40(7). doi:10.1002/bmc.70498

BibTeX
@article{Wang2026,
  author = {Wang, Qiuyan and Li, Rui and Zhang, Huiying},
  title = {Pharmacokinetics and Metabolism of ARV‐393, a BCL6 PROTAC Degrader, in Dogs by UPLC–MS/MS and UPLC‐Q‐Exactive Orbitrap‐HRMS},
  journal = {Biomedical Chromatography},
  year = {2026},
  volume = {40},
  number = {7},
  doi = {10.1002/bmc.70498}
}
Kostenlos starten →